Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Asthma
Interventions
DRUG

tiotropium Respimat low dose

IMP

DRUG

placebo Respimat

placebo representing comparator

DRUG

tiotropium Respimat high dose

IMP

Trial Locations (66)

Unknown

205.444.01004 Boehringer Ingelheim Investigational Site, Plymouth

205.444.01005 Boehringer Ingelheim Investigational Site, Columbia

205.444.01001 Boehringer Ingelheim Investigational Site, Cincinnati

205.444.01014 Boehringer Ingelheim Investigational Site, Oklahoma City

205.444.01002 Boehringer Ingelheim Investigational Site, Charleston

205.444.01012 Boehringer Ingelheim Investigational Site, Charleston

205.444.01013 Boehringer Ingelheim Investigational Site, El Paso

205.444.01003 Boehringer Ingelheim Investigational Site, South Burlington

205.444.56002 Boehringer Ingelheim Investigational Site, Santiago

205.444.56001 Boehringer Ingelheim Investigational Site, Viña del Mar

205.444.56003 Boehringer Ingelheim Investigational Site, Viña del Mar

205.444.49007 Boehringer Ingelheim Investigational Site, Berlin

205.444.49008 Boehringer Ingelheim Investigational Site, Berlin

205.444.49001 Boehringer Ingelheim Investigational Site, Bochum

205.444.49003 Boehringer Ingelheim Investigational Site, Ettenheim

205.444.49006 Boehringer Ingelheim Investigational Site, Koblenz

205.444.49005 Boehringer Ingelheim Investigational Site, Rosenheim

205.444.36007 Boehringer Ingelheim Investigational Site, Ajka

205.444.36005 Boehringer Ingelheim Investigational Site, Budapest

205.444.36008 Boehringer Ingelheim Investigational Site, Budapest

205.444.36006 Boehringer Ingelheim Investigational Site, Kaposvár

205.444.36001 Boehringer Ingelheim Investigational Site, Miskolc

205.444.36002 Boehringer Ingelheim Investigational Site, Mosdós

205.444.36003 Boehringer Ingelheim Investigational Site, Szeged

205.444.36004 Boehringer Ingelheim Investigational Site, Szigetbecse

205.444.39001 Boehringer Ingelheim Investigational Site, Ancona

205.444.39003 Boehringer Ingelheim Investigational Site, Bolzano

205.444.39002 Boehringer Ingelheim Investigational Site, Verona

205.444.37101 Boehringer Ingelheim Investigational Site, Baldone

205.444.37107 Boehringer Ingelheim Investigational Site, Balvi

205.444.37102 Boehringer Ingelheim Investigational Site, Ogre

205.444.37105 Boehringer Ingelheim Investigational Site, Rēzekne

205.444.37106 Boehringer Ingelheim Investigational Site, Riga

205.444.37103 Boehringer Ingelheim Investigational Site, Talsi

205.444.37104 Boehringer Ingelheim Investigational Site, Tukums

205.444.52002 Boehringer Ingelheim Investigational Site, Guadalajara

205.444.52001 Boehringer Ingelheim Investigational Site, Hermosillo

205.444.52003 Boehringer Ingelheim Investigational Site, Monterrey

205.444.70003 Boehringer Ingelheim Investigational Site, Moscow

205.444.70002 Boehringer Ingelheim Investigational Site, Saint Petersburg

205.444.70004 Boehringer Ingelheim Investigational Site, Saint Petersburg

205.444.70005 Boehringer Ingelheim Investigational Site, Saint Petersburg

205.444.70006 Boehringer Ingelheim Investigational Site, Saint Petersburg

205.444.70001 Boehringer Ingelheim Investigational Site, Yaroslavl

205.444.42104 Boehringer Ingelheim Investigational Site, Košice

205.444.42106 Boehringer Ingelheim Investigational Site, Martin

205.444.42101 Boehringer Ingelheim Investigational Site, Nitra

205.444.42105 Boehringer Ingelheim Investigational Site, Rožňava

205.444.82003 Boehringer Ingelheim Investigational Site, Guri-si

205.444.82006 Boehringer Ingelheim Investigational Site, Incheon

205.444.82001 Boehringer Ingelheim Investigational Site, Seoul

205.444.82004 Boehringer Ingelheim Investigational Site, Seoul

205.444.34007 Boehringer Ingelheim Investigational Site, Esplugues Del Llobregat

205.444.34001 Boehringer Ingelheim Investigational Site, Madrid

205.444.34004 Boehringer Ingelheim Investigational Site, Majadahonda (Madrid)

205.444.34005 Boehringer Ingelheim Investigational Site, Marbella

205.444.34006 Boehringer Ingelheim Investigational Site, Sabdadell

205.444.34008 Boehringer Ingelheim Investigational Site, Valencia

205.444.38008 Boehringer Ingelheim Investigational Site, Dnipropetrovsk

205.444.38002 Boehringer Ingelheim Investigational Site, Donetsk

205.444.38005 Boehringer Ingelheim Investigational Site, Kharkiv

205.444.38003 Boehringer Ingelheim Investigational Site, Kiev

205.444.38004 Boehringer Ingelheim Investigational Site, Kiev

205.444.38001 Boehringer Ingelheim Investigational Site, Lviv

205.444.38010 Boehringer Ingelheim Investigational Site, Zaporizhya

205.444.38009 Boehringer Ingelheim Investigational Site, Zaporizhzhya

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY